Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Schatz

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Plos One|July 9, 2020
Overprecision increases subsequent surpriseDon A Moore, Derek Schatz
Blood Advances|July 8, 2020
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapseAndrew Kent, Sumithira Vasu, Derek Schatz, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Medicine|November 14, 2018
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaDaniel A Pollyea, Brett M Stevens, Courtney L Jones, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2021
Empirical audit and review and an assessment of evidentiary value in research on the psychological consequences of scarcityMichael O'Donnell, Amelia S Dev, Stephen Antonoplis, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Plos One|July 9, 2020
Overprecision increases subsequent surpriseDon A Moore, Derek Schatz
Blood Advances|July 8, 2020
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapseAndrew Kent, Sumithira Vasu, Derek Schatz, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Medicine|November 14, 2018
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaDaniel A Pollyea, Brett M Stevens, Courtney L Jones, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2021
Empirical audit and review and an assessment of evidentiary value in research on the psychological consequences of scarcityMichael O'Donnell, Amelia S Dev, Stephen Antonoplis, et al.
Pageof 1